Ibrutinib for mantle cell lymphoma: multicenter retrospective analysis
- Conditions
- Neoplasms
- Registration Number
- KCT0004207
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients with MCL diagnosed by a pathologist (based on the WHO 2017 classification)
1) mantle cell lymphoma
2) leukemic nonnodal mantle cell lymphoma
3) in situ mantle cell neoplasia
- Aged = 19 years
- Relapsed or refractory patients treated with ibrutinib, including relapse after autologous stem cell transplantation
Exclusion Criteria
Patients whose clinical and pathological data are not available
Patients who were not treated with ibrutinib
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Overall survival